iPSC-Derived Oligodendrocyte Progenitors for Efficient Myelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing oligodendrocyte progenitor cells from induced pluripotent stem cells (iPSCs) result in random differentiation, leading to heterogeneous cell preparations contaminated with non-specific cell types, making them unsuitable for clinical use in treating myelin-related disorders due to immune rejection and inefficient myelination.
Innovation Solution
A controlled differentiation protocol for iPSCs to produce highly enriched bipotential oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα, with less than 20% neural progenitor cells expressing Pax-6, ensuring efficient myelination and reduced immune rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If unfractionated brain tissue or general glial progenitor cells are transplanted, then myelinogenic potential is achieved, but the cells yield only patchy remyelination and permit cogeneration of undesired phenotypes including predominantly astrocytic differentiation
Solution Approach 1:
The patent segments the general glial progenitor cell population into specific molecularly-defined subpopulations using co-expression markers (OLIG2 and CD140a/PDGFRα). This segmentation allows isolation of precisely the oligodendrocyte-committed progenitor cells needed for effective remyelination, excluding astrocytic and other undesired phenotypes while maintaining myelinogenic potential.
Solution Approach 2:
The patent applies local quality by defining specific molecular characteristics (co-expression of OLIG2 and CD140a/PDGFRα) for the transplantable cell population. This ensures that only cells with the appropriate local molecular phenotype—committed to oligodendrocyte differentiation—are selected for transplantation, thereby achieving both reliable remyelination and high differentiation purity.
2Reliability
If immortalized multipotential progenitors or oligosphere-derived cells are used, then myelination capacity is achieved, but efficiency remains low due to predominantly astrocytic differentiation
Solution Approach 1:
The patent extracts the specific oligodendrocyte-committed progenitor cell population from heterogeneous progenitor cell populations using molecular marker-based identification (OLIG2+ CD140a/PDGFRα+). This extraction isolates only the cells capable of efficient oligodendrocyte differentiation, removing astrocytic and other undesired lineages, thereby dramatically improving myelination efficiency while preserving capacity.
3Reliability
If fetal human brain tissue is implanted, then oligodendrocytic differentiation and local myelination are achieved, but the cells require fractionation to avoid patchy remyelination and undesired phenotypes
Solution Approach 1:
The patent changes the selection parameter from anatomical/phenotypic fractionation to molecular marker-based identification. By using co-expression of OLIG2 and CD140a/PDGFRα as selection criteria, the method simplifies cell preparation while ensuring high purity of oligodendrocyte-committed progenitors, thereby maintaining reliable differentiation while reducing preparation complexity.
Data Source
Figure 1A~1P
Figure 2
Figure 3A~3J
AI summary
The present invention relates to preparations of induced pluripotent cell-derived oligodendrocyte progenitor cells, and methods of making, isolating, and using these preparations.